Product Images Zafemy

This appears to be a set of medical data related to pregnancy and blood clots. It contains information on the number of women with blood clots out of 10,000 woman-years based on various factors such as pregnancy status and postpartum period. It also includes the range of values for each of these factors.*

ZAFEMY™ is a transdermal system containing norelgestromin and ethinyl estradiol with a strength of 150/35 mcg per day. The product is contraindicated in pregnancy. The remaining text is not-readable.*

ZAFEMY is a transdermal system used to prevent pregnancy. It contains norelgestromin and ethinyl estradiol and is intended to be worn for 7 days as prescribed. The package contains 3 transdermal systems and must be stored at 20° to 25°C (68° to 77°F). ZAFEMY does not protect against HIV infections (AIDS) and other sexually transmitted diseases. The product is distributed by Amneal Pharmaceuticals LLG from Bridgewater, NJ 08807. The RX label must be placed on the package to use it.*

This appears to be a medical document with information on pregnancy and postpartum care. The text includes categories for non-pregnant women, pregnant women, and postpartum women, along with different ranges for certain factors such as weeks of pregnancy and blood clot incidents. The number 0 at the bottom may refer to the number of women with blood clots out of 10,000 woman-years.*

This text presents several studies that address the risk of breast cancer associated with the use of combined oral contraceptives. The studies were conducted between 2002 and 2017, and some of them analyze the risk of both ever-use and current-use. The table at the end of the text presents the effect estimates (OR/RR) obtained by the studies.*